Goldman Sachs’s EyePoint Pharmaceuticals EYPT Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $12.1M | Sell |
|
|||||
2025
Q1 | $8.3M | Sell |
|
|||||
2024
Q4 | $12.4M | Buy |
|
|||||
2024
Q3 | $9.71M | Buy |
|
|||||
2024
Q2 | $6.89M | Sell |
|
|||||
2024
Q1 | $17.4M | Buy |
|
|||||
2023
Q4 | $13.1M | Sell |
|
|||||
2023
Q3 | $4.8M | Buy |
|
|||||
2023
Q2 | $3.72M | Sell |
|
|||||
2023
Q1 | $2.07M | Sell |
|
|||||
2022
Q4 | $2.67M | Sell |
|
|||||
2022
Q3 | $6.75M | Sell |
|
|||||
2022
Q2 | $6.99M | Buy |
|
|||||
2022
Q1 | $10.6M | Buy |
|
|||||
2021
Q4 | $7.61M | Buy |
|
|||||
2021
Q3 | $407K | Sell |
|
|||||
2021
Q2 | $2.19M | Buy |
|
|||||
2021
Q1 | $1.4M | Buy |
|
|||||
2020
Q4 | – | Sell |
|
|||||
2020
Q3 | $64K | Sell |
|
|||||
2020
Q2 | $107K | Buy |
|
|||||
2020
Q1 | $96K | Buy |
|
|||||
2019
Q4 | $125K | Buy |
|
|||||
2019
Q3 | $109K | Buy |
|
|||||
2019
Q2 | $66K | Sell |
|
|||||
2019
Q1 | $560K | Buy |
|
|||||
2018
Q4 | $79K | Buy |
|
|||||
2018
Q3 | $119K | Sell |
|
|||||
2018
Q2 | $88K | Buy |
|
|||||
2017
Q4 | – | Sell |
|
|||||
2017
Q3 | $14K | Buy |
|
|||||
2017
Q2 | $18K | Buy |
|
|||||
2016
Q3 | – | Sell |
|
|||||
2016
Q2 | $57K | Sell |
|
|||||
2016
Q1 | $61K | Sell |
|
|||||
2015
Q4 | $128K | Sell |
|
|||||
2015
Q3 | $282K | Sell |
|
|||||
2015
Q2 | $447K | Sell |
|
|||||
2015
Q1 | $478K | Sell |
|
|||||
2014
Q4 | $534K | Buy |
|
|||||
2014
Q3 | $31K | Buy |
|